Oncology Biosimilars Market with COVID-19 Impact Analysis, By Drug Class (Monoclonal Antibodies, G-CSF, Hematopoietic Agents, Others), By Type of Cancer (Breast Cancer, Lung Cancer, Stomach Cancer, Prostate Cancer, Cervical Cancer, Blood Cancer, Brain Cancer, Others), By Distribution Channel (Retail Pharmacies, Hospital Pharmacies, and Online Pharmacies), By Country, and By Region Industry Analysis, Market Size, Market Share & Forecast from 2023-2030
REPORT HIGHLIGHT
Oncology Biosimilars Market size was valued at USD 4,200.12 Million in 2022, expanding at a CAGR of 10.67% from 2023 to 2030.
Oncology biosimilars are biological medicines created to be strikingly comparable to and functionally equal to the oncology reference biologics, which are currently available in pharmaceuticals. These biosimilars are created to offer affordable cancer therapy choices. They go through thorough comparative tests to show that they are comparable in terms of safety, quality, and efficacy. Oncology biosimilars seek to improve patient access to essential cancer treatments while also perhaps lowering healthcare costs by providing therapeutic results that are equivalent to those of the unique oncology biologics. A comprehensive regulatory review is required for their approval to guarantee patient safety and maintain cancer treatment requirements.
Oncology Biosimilars Market- Market Dynamics
- Increasing prevalence of cancer
The rising incidence of cancer is the primary factor driving the market for oncology biosimilars. The International Agency for Research on Cancer (IARC) predicts that by 2040, there would be 16.3 million cancer-related deaths globally and 27.5 million new cancer diagnoses. Normal cells go through a multi-stage process that normally goes from a pre-cancerous lesions to a tumor that is malignant when cancer begins. Aging persons often have less effective cellular repair systems in addition to the normal risk buildup. Smoking, consuming alcohol, adopting a poor diet, leading a life of inactivity, and air pollution all increase the chance of developing cancer.
Oncology Biosimilars Market- Key Insights
- As per the analysis shared by our research analyst, the global Oncology Biosimilars market is estimated to grow annually at a CAGR of around 10.67% over the forecast period (2023-2030)
- The Oncology Biosimilars industry is projected to grow at a significant rate due to the growing prevalence of cancer
- Based on drug class segmentation, G-CSF was predicted to show maximum market share in the year 2022
- Based on type of cancer, breast cancer was the leading type in 2022
- Based on distribution channel segmentation, hospital retail was the leading type in 2022
- On the basis of region, North America was the leading revenue generator in 2022
Oncology Biosimilars Market- Segmentation Analysis:
The Global Oncology Biosimilars Market is segmented on the basis of Drug Class, Type of Cancer, Distribution Channel, and Region.
The market is divided into categories based on Drug Class: monoclonal antibodies, G-CSF, hematopoietic agents, and others. The higher market share of G-CSF is a result of the widespread use of G-CSF after chemotherapy to aid in the recovery of white blood cells following cancer treatment. Granulocyte colony-stimulating factors (G-CSF) are available in a variety of forms, including filgrastim, lenograstim, long-acting filgrastim, and pegfilgrastim.
The market is divided into categories based on type of cancer: breast cancer, lung cancer, stomach cancer, prostate cancer, cervical cancer, blood cancer, brain cancer, and others. Due to the highest percentage of breast cancer cases globally among all malignancies, the breast cancer sector commands the market. The risk of breast cancer is increased by a number of variables, including age, obesity, alcoholism, cigarette use, postmenopausal hormone treatment, exposure to radiation history, and family history of the disease.
Oncology Biosimilars Market- Geographical Insights
Geographically, this market is widespread into the regions of North America, Latin America, Europe, Asia Pacific, and the Middle East and Africa. These regions are further divided as per the nations bringing business. The Asia Pacific region is a developing market, with Korea, China, and India, in particular, making strides with cancer biosimilars. Due to a large population, rising health consciousness, rising healthcare expenditure, and decreased manufacturing costs, they also reflect the market\'s future potential.
Oncology Biosimilars Market- Competitive Landscape:
Companies sell their products through a variety of channels, including corporate websites, e-commerce websites, retailers, distributors, and end consumers. Products makers compete on a variety of aspects, including product costs, performance, product making, Distribution Channel, reputation, and availability. Some of the primary techniques used by corporations to strengthen their reach and expand their market share include new product launches, distribution network development, R&D spending, and mergers and acquisitions. For instance, May 2022, Abevmy (bevacizumab), the third cancer biosimilar produced by Biocon Biologics and Viatris, has made accessible in Canada.
Recent Developments:
- September 2022Celltrion USA received FDA permission for using its oncology biosimilar vegzelma (bevacizumab-add) to treat six different forms of cancer.
SCOPE OF THE REPORT
The scope of this report covers the market by its major segments, which include as follows:
GLOBAL ONCOLOGY BIOSIMILARS MARKET KEY PLAYERS
- Teva Pharmaceuticals
- STADA Arzneimittel AG
- Shanghai Henlius Biotech
- Sandoz (Novartis)
- Samsung Bioepis
- Pfizer
- Pfenex Inc.
- Mylan
- Innovent Biologics
- Reddy\'s Laboratories
- Celltrion Healthcare
- Biocon
- Apotex
- Amgen
- Accord Healthcare
GLOBAL ONCOLOGY BIOSIMILARS MARKET, BY DRUG CLASS
- Monoclonal Antibodies
- G-CSF
- Hematopoietic Agents
- Others
GLOBAL ONCOLOGY BIOSIMILARS MARKET, BY TYPE OF CANCER
- Breast Cancer
- Lung Cancer
- Stomach Cancer
- Prostate Cancer
- Cervical Cancer
- Blood Cancer
- Brain Cancer
- Others
GLOBAL ONCOLOGY BIOSIMILARS MARKET, BY DISTRIBUTION
- Retail Pharmacies
- Hospital Pharmacies
- Online Pharmacies
GLOBAL ONCOLOGY BIOSIMILARS MARKET, BY REGION
- North America
- The U.S.
- Canada
- Europe
- Germany
- France
- Italy
- Spain
- United Kingdom
- Russia
- Netherlands
- Sweden
- Poland
- Rest of Europe
- Asia Pacific
- India
- China
- South Korea
- Japan
- Australia
- Thailand
- Indonesia
- Philippines
- Rest of APAC
- Latin America
- Brazil
- Mexico
- Argentina
- Colombia
- Rest of LATAM
- The Middle East and Africa
- Saudi Arabia
- United Arab Emirates
- Israel
- Turkey
- Algeria
- Egypt
- Rest of MEA
TABLE OF CONTENT
1. Oncology Biosimilars Market Overview
1.1. Study Scope
1.2. Market Estimation Years
2. Executive Summary
2.1. Market Snippet
2.1.1. Oncology Biosimilars Market Snippet by Drug Class
2.1.2. Oncology Biosimilars Market Snippet by Type of Cancer
2.1.3. Oncology Biosimilars Market Snippet by Distribution Channel
2.1.4. Oncology Biosimilars Market Snippet by Country
2.1.5. Oncology Biosimilars Market Snippet by Region
2.2. Competitive Insights
3. Oncology Biosimilars Key Market Trends
3.1. Oncology Biosimilars Market Drivers
3.1.1. Impact Analysis of Market Drivers
3.2. Oncology Biosimilars Market Restraints
3.2.1. Impact Analysis of Market Restraints
3.3. Oncology Biosimilars Market Opportunities
3.4. Oncology Biosimilars Market Future Trends
4. Oncology Biosimilars Industry Study
4.1. PEST Analysis
4.2. Porter’s Five Forces Analysis
4.3. Growth Prospect Mapping
4.4. Regulatory Framework Analysis
5. Oncology Biosimilars Market: COVID-19 Impact Analysis
5.1. Pre-COVID-19 Impact Analysis
5.2. Post-COVID-19 Impact Analysis
5.2.1. Top Performing Segments
5.2.2. Marginal Growth Segments
5.2.3. Top Looser Segments
5.2.4. Marginal Loss Segments
6. Oncology Biosimilars Market Landscape
6.1. Oncology Biosimilars Market Share Analysis, 2022
6.2. Breakdown Data, by Key Manufacturer
6.2.1. Established Players’ Analysis
6.2.2. Emerging Players’ Analysis
7. Oncology Biosimilars Market – By Drug Class
7.1. Overview
7.1.1. Segment Share Analysis, By Drug Class, 2022 & 2030 (%)
7.1.2. Monoclonal Antibodies
7.1.3. G-CSF
7.1.4. Hematopoietic Agents
7.1.5. Others
8. Oncology Biosimilars Market – By Type of Cancer
8.1. Overview
8.1.1. Segment Share Analysis, By Type of Cancer, 2022 & 2030 (%)
8.1.2. Breast Cancer
8.1.3. Lung Cancer
8.1.4. Stomach Cancer
8.1.5. Prostate Cancer
8.1.6. Cervical Cancer
8.1.7. Blood Cancer
8.1.8. Brain Cancer
8.1.9. Others
9. Oncology Biosimilars Market – By Distribution Channel
9.1. Overview
9.1.1. Segment Share Analysis, By Distribution Channel, 2022 & 2030 (%)
9.1.2. Retail Pharmacies
9.1.3. Hospital Pharmacies
9.1.4. Online Pharmacies
10. Oncology Biosimilars Market– By Geography
10.1. Introduction
10.1.1. Segment Share Analysis, By Geography, 2022 & 2030 (%)
10.2. North America
10.2.1. Overview
10.2.2. Oncology Biosimilars Key Manufacturers in North America
10.2.3. North America Market Size and Forecast, By Country, 2018 - 2030 (US$ Million)
10.2.4. North America Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
10.2.5. North America Market Size and Forecast, By Type of Cancer, 2018 - 2030 (US$ Million)
10.2.6. North America Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
10.2.7. U.S.
10.2.7.1. Overview
10.2.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
10.2.7.3. U.S. Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
10.2.7.4. U.S. Market Size and Forecast, By Type of Cancer, 2018 - 2030 (US$ Million)
10.2.7.5. U.S. Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
10.2.8. Canada
10.2.8.1. Overview
10.2.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
10.2.8.3. Canada Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
10.2.8.4. Canada Market Size and Forecast, By Type of Cancer, 2018 - 2030 (US$ Million)
10.2.8.5. Canada Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
10.3. Europe
10.3.1. Overview
10.3.2. Oncology Biosimilars Key Manufacturers in Europe
10.3.3. Europe Market Size and Forecast, By Country, 2018 - 2030 (US$ Million)
10.3.4. Europe Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
10.3.5. Europe Market Size and Forecast, By Type of Cancer, 2018 - 2030 (US$ Million)
10.3.6. Europe Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
10.3.7. Germany
10.3.7.1. Overview
10.3.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
10.3.7.3. Germany Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
10.3.7.4. Germany Market Size and Forecast, By Type of Cancer, 2018 - 2030 (US$ Million)
10.3.7.5. Germany Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
10.3.8. Italy
10.3.8.1. Overview
10.3.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
10.3.8.3. Italy Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
10.3.8.4. Italy Market Size and Forecast, By Type of Cancer, 2018 - 2030 (US$ Million)
10.3.8.5. Italy Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
10.3.9. United Kingdom
10.3.9.1. Overview
10.3.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
10.3.9.3. United Kingdom Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
10.3.9.4. United Kingdom Market Size and Forecast, By Type of Cancer, 2018 - 2030 (US$ Million)
10.3.9.5. United Kingdom Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
10.3.10. France
10.3.10.1. Overview
10.3.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
10.3.10.3. France Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
10.3.10.4. France Market Size and Forecast, By Type of Cancer, 2018 - 2030 (US$ Million)
10.3.10.5. France Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
10.3.11. Russia
10.3.11.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
10.3.11.2. Russia Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
10.3.11.3. Russia Market Size and Forecast, By Type of Cancer, 2018 - 2030 (US$ Million)
10.3.11.4. Russia Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
10.3.12. Netherlands
10.3.12.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
10.3.12.2. Netherlands Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
10.3.12.3. Netherlands Market Size and Forecast, By Type of Cancer, 2018 - 2030 (US$ Million)
10.3.12.4. Netherlands Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
10.3.13. Sweden
10.3.13.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
10.3.13.2. Sweden Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
10.3.13.3. Sweden Market Size and Forecast, By Type of Cancer, 2018 - 2030 (US$ Million)
10.3.13.4. Sweden Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
10.3.14. Poland
10.3.14.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
10.3.14.2. Poland Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
10.3.14.3. Poland Market Size and Forecast, By Type of Cancer, 2018 - 2030 (US$ Million)
10.3.14.4. Poland Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
10.3.15. Rest of Europe
10.3.15.1. Overview
10.3.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
10.3.15.3. Rest of the Europe Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
10.3.15.4. Rest of the Europe Market Size and Forecast, By Type of Cancer, 2018 - 2030 (US$ Million)
10.3.15.5. Rest of the Europe Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
10.4. Asia Pacific (APAC)
10.4.1. Overview
10.4.2. Oncology Biosimilars Key Manufacturers in Asia Pacific
10.4.3. Asia Pacific Market Size and Forecast, By Country, 2018 - 2030 (US$ Million)
10.4.4. Asia Pacific Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
10.4.5. Asia Pacific Market Size and Forecast, By Type of Cancer, 2018 - 2030 (US$ Million)
10.4.6. Asia Pacific Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
10.4.7. India
10.4.7.1. Overview
10.4.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
10.4.7.3. India Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
10.4.7.4. India Market Size and Forecast, By Type of Cancer, 2018 - 2030 (US$ Million)
10.4.7.5. India Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
10.4.8. China
10.4.8.1. Overview
10.4.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
10.4.8.3. China Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
10.4.8.4. China Market Size and Forecast, By Type of Cancer, 2018 - 2030 (US$ Million)
10.4.8.5. China Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
10.4.9. Japan
10.4.9.1. Overview
10.4.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
10.4.9.3. Japan Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
10.4.9.4. Japan Market Size and Forecast, By Type of Cancer, 2018 - 2030 (US$ Million)
10.4.9.5. Japan Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
10.4.10. South Korea
10.4.10.1. Overview
10.4.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
10.4.10.3. South Korea Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
10.4.10.4. South Korea Market Size and Forecast, By Type of Cancer, 2018 - 2030 (US$ Million)
10.4.10.5. South Korea Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
10.4.11. Australia
10.4.11.1. Overview
10.4.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
10.4.11.3. Australia Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
10.4.11.4. Australia Market Size and Forecast, By Type of Cancer, 2018 - 2030 (US$ Million)
10.4.11.5. Australia Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
10.4.12. Thailand
10.4.12.1. Overview
10.4.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
10.4.12.3. Thailand Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
10.4.12.4. Thailand Market Size and Forecast, By Type of Cancer, 2018 - 2030 (US$ Million)
10.4.12.5. Thailand Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
10.4.13. Indonesia
10.4.13.1. Overview
10.4.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
10.4.13.3. Indonesia Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
10.4.13.4. Indonesia Market Size and Forecast, By Type of Cancer, 2018 - 2030 (US$ Million)
10.4.13.5. Indonesia Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
10.4.14. Philippines
10.4.14.1. Overview
10.4.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
10.4.14.3. Philippines Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
10.4.14.4. Philippines Market Size and Forecast, By Type of Cancer, 2018 - 2030 (US$ Million)
10.4.14.5. Philippines Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
10.4.15. Rest of APAC
10.4.15.1. Overview
10.4.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
10.4.15.3. Rest of APAC Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
10.4.15.4. Rest of APAC Market Size and Forecast, By Type of Cancer, 2018 - 2030 (US$ Million)
10.4.15.5. Rest of APAC Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
10.5. Latin America
10.5.1. Overview
10.5.2. Oncology Biosimilars Key Manufacturers in Latin America
10.5.3. Latin America Market Size and Forecast, By Country, 2018 - 2030 (US$ Million)
10.5.4. Latin America Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
10.5.5. Latin America Market Size and Forecast, By Type of Cancer, 2018 - 2030 (US$ Million)
10.5.6. Latin America Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
10.5.7. Brazil
10.5.7.1. Overview
10.5.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
10.5.7.3. Brazil Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
10.5.7.4. Brazil Market Size and Forecast, By Type of Cancer, 2018 - 2030 (US$ Million)
10.5.7.5. Brazil Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
10.5.8. Mexico
10.5.8.1. Overview
10.5.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
10.5.8.3. Mexico Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
10.5.8.4. Mexico Market Size and Forecast, By Type of Cancer, 2018 - 2030 (US$ Million)
10.5.8.5. Mexico Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
10.5.9. Argentina
10.5.9.1. Overview
10.5.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
10.5.9.3. Argentina Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
10.5.9.4. Argentina Market Size and Forecast, By Type of Cancer, 2018 - 2030 (US$ Million)
10.5.9.5. Argentina Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
10.5.10. Colombia
10.5.10.1. Overview
10.5.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
10.5.10.3. Colombia Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
10.5.10.4. Colombia Market Size and Forecast, By Type of Cancer, 2018 - 2030 (US$ Million)
10.5.10.5. Colombia Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
10.5.11. Rest of LATAM
10.5.11.1. Overview
10.5.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
10.5.11.3. Rest of LATAM Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
10.5.11.4. Rest of LATAM Market Size and Forecast, By Type of Cancer, 2018 - 2030 (US$ Million)
10.5.11.5. Rest of LATAM Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
10.6. Middle East and Africa
10.6.1. Overview
10.6.2. Oncology Biosimilars Key Manufacturers in Middle East and Africa
10.6.3. Middle East and Africa Market Size and Forecast, By Country, 2018 - 2030 (US$ Million)
10.6.4. Middle East and Africa Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
10.6.5. Middle East and Africa Market Size and Forecast, By Type of Cancer, 2018 - 2030 (US$ Million)
10.6.6. Middle East and Africa Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
10.6.7. Saudi Arabia
10.6.7.1. Overview
10.6.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
10.6.7.3. Saudi Arabia Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
10.6.7.4. Saudi Arabia Market Size and Forecast, By Type of Cancer, 2018 - 2030 (US$ Million)
10.6.7.5. Saudi Arabia Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
10.6.8. United Arab Emirates
10.6.8.1. Overview
10.6.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
10.6.8.3. United Arab Emirates Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
10.6.8.4. United Arab Emirates Market Size and Forecast, By Type of Cancer, 2018 - 2030 (US$ Million)
10.6.8.5. United Arab Emirates Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
10.6.9. Israel
10.6.9.1. Overview
10.6.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
10.6.9.3. Israel Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
10.6.9.4. Israel Market Size and Forecast, By Type of Cancer, 2018 - 2030 (US$ Million)
10.6.9.5. Israel Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
10.6.10. Turkey
10.6.10.1. Overview
10.6.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
10.6.10.3. Turkey Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
10.6.10.4. Turkey Market Size and Forecast, By Type of Cancer, 2018 - 2030 (US$ Million)
10.6.10.5. Turkey Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
10.6.11. Algeria
10.6.11.1. Overview
10.6.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
10.6.11.3. Algeria Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
10.6.11.4. Algeria Market Size and Forecast, By Type of Cancer, 2018 - 2030 (US$ Million)
10.6.11.5. Algeria Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
10.6.12. Egypt
10.6.12.1. Overview
10.6.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
10.6.12.3. Egypt Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
10.6.12.4. Egypt Market Size and Forecast, By Type of Cancer, 2018 - 2030 (US$ Million)
10.6.12.5. Egypt Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
10.6.13. Rest of MEA
10.6.13.1. Overview
10.6.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
10.6.13.3. Rest of MEA Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
10.6.13.4. Rest of MEA Market Size and Forecast, By Type of Cancer, 2018 - 2030 (US$ Million)
10.6.13.5. Rest of MEA Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
11. Key Vendor Analysis- Oncology Biosimilars Industry
11.1. Competitive Dashboard
11.2. Company Profiles
11.2.1. Teva Pharmaceuticals
11.2.2. STADA Arzneimittel AG
11.2.3. Shanghai Henlius Biotech
11.2.4. Sandoz (Novartis)
11.2.5. Samsung Bioepis
11.2.6. Pfizer
11.2.7. Pfenex Inc.
11.2.8. Mylan
11.2.9. Innovent Biologics
11.2.10. Dr. Reddy\'s Laboratories
11.2.11. Celltrion Healthcare
11.2.12. Biocon
11.2.13. Apotex
11.2.14. Amgen
11.2.15. Accord Healthcare
12. 360 Degree Analyst View
13. Appendix
13.1. Research Methodology
13.2. References
13.3. Abbreviations
13.4. Disclaimer
13.5. Contact Us
